Correction of previously communicated press release
Press release
30 June 2023 14:50 CEST
Correction of previously communicated press release
Episurf Medical AB (publ) ("Episurf") announces correction in relation to the press release "RECORD DAY FOR FREE WARRANTS OF SERIES TO4B AS WELL AS INFORMATION ABOUT PERIOD FOR EXERCISING WARRANTS OF SERIES TO4B" published on May 23, 2018. The press release incorrectly stated that subscription of shares through the exercise of warrants of series TO4B will be possible during the period Thursday, November 9, 2023 until Thursday, November 23, 2023.
According to the terms and conditions of the warrants, the exercise of warrants below an aggregated amount of SEK 500,000 may take place on ten occasions during the two-week period preceding the day of 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months after the registration date of the decision to issue the warrants at the Swedish Companies Registration Office. The issue of the warrants of series TO4B was registered with the Swedish Companies Registration Office on Wednesday 23 May 2018. Accordingly, the last subscription period took place on Tuesday, May 9, 2023 until Tuesday, May 23, 2023, which was the two-week period preceding the day of 60 months after the registration date of the decision. Furthermore, the first subscription period would correctly have taken place on Friday November 9, 2018 until Friday November 23, 2018. No further possibility to subscribe for shares through the exercise of warrants of series TO4B will be given.
The previous press release from 23 May 2018 is therefore corrected by deleting the following text found in the list of subscription periods: "Thursday, November 9, 2023 until Thursday, November 23, 2023". A corresponding correction is made to the Swedish version of the press release where the following text is deleted: "Torsdagen den 9 november 2023 till och med torsdagen den 23 november 2023".
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 14:50 CEST on 30 June 2023.
Tags: